Nubeqa
FDA Approves Nubeqa for Metastatic Castration-Sensitive Prostate Cancer
The FDA has approved Nubeqa for metastatic castration-sensitive prostate cancer.
JUNE 6, 2025
Darolutamide Triplet Therapy Improves Survival In mHSPC
Adding the androgen receptor inhibitor darolutamide (Nubeqa, Bayer/Orion) to androgen deprivation therapy (ADT) and ...
APRIL 12, 2022
FDA Approves Nubeqa to Treat Prostate Cancer
Bayer's Nubeqa was approved for the treatment of patients with nonmetastatic castration-resistant prostate ...
AUGUST 1, 2019
Load more